OBJECTIVE: To review 13 years of experience using fused crystalline @entity251 implants for @entity342 replacement therapy in order to identify pattern of usage (including continuation rates) and adverse events emerging during therapy and factors associated with adverse events including implant extrusions. DESIGN: Retrospective review of prospectively collected data on characteristics of @entity1 and implant procedures performed as well as adverse events reported during routine follow-up. @entity1 : Over 13 years 973 implant procedures using fused crystalline @entity251 implants were performed in 221 @entity1 . MEASUREMENTS: Continuation rates and adverse events such as extrusions, @entity548 , @entity281 or others were recorded and analysed in relationship to characteristics of the @entity1 and the implant procedure performed. RESULTS: Overall rate of adverse events (108/73, 11.1%) was significantly related to increased numbers of implants (4.2 +/- 0.1 vs 4.0 +/- 0.03, P = 0.031) and higher levels of physical activity at work (P = 0.030). The most common adverse effect was extrusion (83/973, 8.5%) which was related to occupational classification (P = 0.033) and increasing work activity (P = 0.044) and occurred more frequently than by chance in multiple (16 vs 3.3 expected) rather than single (65 vs 76.1 expected) episodes. Bleeding (22/973, 2.3%) was significantly associated with an increased number of implants (4.5 +/- 0.2 vs 4.0 +/- 0.03, P = 0.020) but even in the worst cases (3/22) it was of minor clinical importance. Infection was rare (6/973, 0.6%) but occurred more among thinner @entity1 . The overall continuation rate was 92.7% increasing from 86% after the first implantation to > 99% after the tenth implant. CONCLUSIONS: This study demonstrates the very satisfactory clinical acceptability of @entity251 pellet implants for @entity342 replacement therapy within a single unit with experienced operators. The only regular adverse effect is extrusion, which may be related to mechanical factors such as habitual work activity but also possibly procedural factors. Other adverse effects such as @entity548 , @entity281 and @entity82 were rare. An improved method of implant delivery would enhance this old but durable technology.

An analysis of XXXX implants for @entity342 replacement therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS', 'men'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']
@entity251 :: (MESH:D013739,Chemical) :: ['testosterone']
